Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Karyopharm Therapeutics ( (KPTI) ).
On February 18, 2026, Karyopharm Therapeutics Inc. stockholders approved an amendment to the company’s Restated Certificate of Incorporation to increase total authorized capital stock from 58,333,333 to 111,000,000 shares and authorized common stock from 53,333,333 to 106,000,000 shares. The company filed the corresponding Certificate of Amendment with the Delaware Secretary of State that same day, significantly expanding its capacity to issue new shares for potential future financing or strategic purposes.
At the same February 18, 2026 Special Meeting, stockholders also approved a proposal that would have allowed adjournment of the meeting to solicit additional proxies if support for the share increase had been insufficient. Because a quorum was present and votes in favor of the Authorized Shares Proposal were adequate, adjournment proved unnecessary, underscoring strong shareholder backing for the capital structure expansion.
The most recent analyst rating on (KPTI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.
Spark’s Take on KPTI Stock
According to Spark, TipRanks’ AI Analyst, KPTI is a Neutral.
Score is held down primarily by weak financial fundamentals (large ongoing losses, negative equity, and cash burn with a tight runway). Offsetting this are constructive technical momentum and a mixed-but-catalyst-driven earnings outlook with near-term Phase III readouts and ongoing cost reductions, while valuation remains constrained by loss-making results.
To see Spark’s full report on KPTI stock, click here.
More about Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics, with its operations organized as a Delaware corporation. The company’s capital structure is based on common stock, and changes to its authorized share count can materially affect its financing flexibility and corporate strategy in the public markets.
Average Trading Volume: 416,480
Technical Sentiment Signal: Hold
Current Market Cap: $172.4M
For detailed information about KPTI stock, go to TipRanks’ Stock Analysis page.